Home › NCT07712575
A Study of V132 in Healthy Older Participants (V132-001)
RecruitingPhase 1Healthy volunteers welcome
A Phase 1, Randomized, Double-Blind, Comparator-Controlled Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of V132 in Healthy Older Participants
Who can join
Ages 50 to 75 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: The key inclusion criteria include but are not limited to the following: * Is in good health * Has body mass index (BMI) within 18.0 to 35.0 kg/m\^2 (inclusive) Exclusion Criteria: The key exclusion criteria include but are not limited to the following: * Has a history of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease within 3 years prior to receiving study vaccination * Has received a pneumococcal polysaccharide vaccine in the previous 10 years, has received any pneumococcal conjugate vaccine at any time prior to this study
About the study
The goal of this study is to learn about the safety and immune response to the V132 vaccine in healthy older adults.
What is being tested
- V132 Formulation 1 (biological)
- V132 Formulation 2 (biological)
- V132 Formulation 3 (biological)
- PREVNAR 20™ (biological)
- CAPVAXIVE™ (biological)
Sponsor: Merck Sharp & Dohme LLC · Participants: 280 · Started: Aug 12, 2026
Contact the study team
- Toll Free Number · Phone: 1-888-577-8839
Official record on ClinicalTrials.gov — NCT07712575
Locations in the U.S.
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.